Medical  Explorer

Custom Search

Drugs A to Z  :  A  B  C  D  E  F  G  H  I  J  K  L  M  N  O  P  R  S  T  U  V  W  X  Y  Z
Medicinal Ingredients : A  B  C  D  E  F  G  H  I  J  K  L  M  N  O  P  Q  R  S  T  U  V  W  X  Y  Z

Beauty Products : A  B  C  D  E  F  G  I  M  N  O  P  R  S  T  V

Aging      Allergies     Alzheimer's      Arthritis    Asthma      Bacteria   new Cancer    Chickenpox     Colds     Constipation      Diabetes      Epilepsy     Fatigue     Fever     Genetics       Haemorrhoids       newHeadaches      Hepatitis    Immunity      Infection      Insomnia       Leprosy       Menopause      Obesity      Osteoporosis     Other Diseases    Pain      PMS     Parasites     Sinusitis     newStroke     Toxicology    Urology

Arthritis medications
newGeneral Health
Medicinal food
Chinese medicine
OTC Drugs
Health Products

Anti-inflammatory and anti-rheumatic product, non-steroid, acetic acid derivative and related substance.

The active substance is sodium-(o-[(2,6-dichlorophenyl)amino]-phenyl acetate (=diclofenac sodium).
One Voltaren ampoule of 3 mL contains 75 mg of diclofenac sodium.
For excipients, see section EXCIPIENTS.
Solution for injection.

Clear, colourless to faintly yellow liquid.

Intramuscular injection
Treatment of:
Exacerbations of inflammatory and degenerative forms of rheumatism: rheumatoid arthritis, ankylosing spondylitis, osteoarthritis, spondylarthritis, painful syndromes of the vertebral column, non-articular rheumatism.
Acute attacks of gout.
Renal colic and biliary colic.
Post-traumatic and post-operative pain, inflammation and swelling.

Intravenous infusion
Treatment or prevention of post-operative pain in a hospital setting.

As a general recommendation, the dose should be individually adjusted and the lowest effective dose given for the shortest possible duration.

Voltaren solution for injection should not be given for more than 2 days; if necessary, treatment can be continued with Voltaren tablets or suppositories.

Intramuscular injection
The following directions for intramuscular injection must be followed in order to avoid damage to a nerve or other tissue at the injection site.

The dose is generally one 75 mg ampoule daily, given by deep intragluteal injection into file upper outer quadrant. In severe cases (e.g. colic), the daily dose ran exceptionally be
increased to two injections of 75 mg, separated by an interval of a few hours (one into each buttock). Alternatively, one ampoule of 75 mg can be combined with other pharmaceutical forms of Voltaren (e.g. tablets, suppositories) UP to a total maximum daily dose of 150 mg.

Intravenous infusion
Voltaren solution for injection must not be given as an intravenous bolus injection.

Immediately before starting an intravenous infusion, Voltaren solution for injection must be diluted with saline 0.9% or glucose 5% infusion solution buffered with sodium bicarbonate according to the instructions given in section


Two alternative dosage regimens of Voltaren solution for injection are recommended.

For the treatment of moderate to severe post-operative pain, 75 mg should be infused continuously over a period of 30 minutes to 2 hours. If necessary, treatment may be repeated after a few hours, but the dose should not exceed 150 mg within any period of 24 hours.

For the prevention of post-operative pain, a loading dose of 25 mg to 50 mg should be infused after surgery over 15 minutes to 1 hour, followed by a continuous infusion of about 5 mg per hour up to a maximum daily dose of 150 mg.

Children and adolescents
Because of their dosage strength, the ampoules of Voltaren solution for injection are not suitable for children and adolescents.

Known hypersensitivity to the active substance, sodium rnetabisulphite or any of the other excipients.
Active gastric or intestinal ulcer, bleeding or perforation.
Last trimester of pregnancy (see section PREGNANCY AND LACTATION).
Severe hepatic renal and cardiac failure (see section SPECIAL WARNINGS AND PRECAUTIONS FOR USE).
Like other non-steroidal and-inflammatory drugs (NSAIDs), Voltaren is also contraindicated in patients in whom attacks of asthma, urticaria, or acute rhinitis are precipitated by acetylsalicylic acid or other NSAIDs.


Gastrointestinal bleeding ulceration or perforation, which can be fatal, have been reported with all NSAIDs and may occur at any time during treatment, with or without warning symptoms or a previous history of serious gastrointestinal events. They generally have more serious consequences in the elderly. it gastrointestinal bleeding or ulceration occur in patients receiving Voltaren, the medicinal product should be withdrawn.

Serious skin reactions, some of them fatal, including exfoliative dermatitis, Stevens-Johnson syndrome and toxic epidermal necrolysis, have been reported very rarely in association with the use of NSAIDS, including Voltaren (see section UNDESIRABLE EFFECTS). Patients appear to be at highest risk of these reactions early in the course of therapy, the onset of the reaction occurring in the majority of cases within the first month of treatment. Voltaren should be discontinued at the first appearance of skin rash, mucosal lesions or any other sign of hypersensitivity. As with other NSAIDs, allergic reactions, including anaphylactic/anaphylactoid reactions, can also occur in rare cases without earlier exposure to diclofenac. The sodium rnetabisulphite in the solution for injection can also lead to isolated severe hypersensitivity reactions and bronchospasm. Like other NSAIDs, Voltaren may mask the signs and symptoms of infection due to its pharmacodynamic properties.

The concomitant use of Voltaren with systemic NSAIDs including cyclooxygenase-2 selective inhibitors, should be avoided due to the absence of any evidence demonstrating synergistic benefits and the potential for additive undesirable effects.

Caution is indicated in the elderly on basic medical grounds. In particular it is recommended that the lowest effective dose be used in frail elderly patients or those with a low body weight.

Pre-existing asthma
In patients with asthma, seasonal allergic rhinitis, swelling of the nasal mucosa (i.e. nasal polyps), chronic obstructive pulmonary diseases or chronic infections of the respiratory tract (especially if linked to allergic rhinitis-like symptoms), reactions on NSAIDs like asthma exacerbations (so-called intolerance to analgesics / analgesics-asthma), Quincke's oedema or urticaria are more frequent than in other patients. Therefore special precaution is recommended in such patients (readiness for emergency). This is applicable as well for patients who are allergic to other substances, e.g. with skin reactions, pruritus or urticaria. Special caution is recommended when Voltaren is used parenterally in patients with bronchial asthma because symptoms may be exacerbated.

Gastrointestinal effects
As with all NSAIDs, close medical surveillance is imperative and particular caution should be exercised when prescribing Voltaren in patients with symptoms indicative of gastrointestinal (GI) disorders or with a history suggestive of gastric or intestinal ulceration, bleeding or perforation, (see section UNDESIRABLE EFFECTS). The risk of GI bleeding is higher with increasing NSAID doses and in patients with a history of ulcer, particularly if complicated with haemorrhage or perforation and in the elderly.

To reduce the risk of GI toxicity in patients with a history of ulcer, particularly if complicated with haemorrhage or perforation, and in the elderly, the treatment should be initiated and maintained at the lowest effective dose.

Combination therapy with protective agents (e.g. proton pump inhibitors or misoprostol) should be considered for these patients, and also for patients requiring concomitant use of medicinal products containing low-dose acetylsalicylic acid (ASA)/aspirin, or other medicinal products likely to increase gastrointestinal risk.

Patients with a history of GI toxicity, particularly the elderly, should report any unusual abdominal symptoms (especially GI bleeding). Caution is recommended in patients receiving concomitant medications which could increase the risk of ulceration or bleeding, such as systemic corticosteroids, anticoagulants, anti-platelet agents or selective serotonin-reuptake inhibitors (see section INTERACTIONS).

Close medical surveillance and caution should also be exercised in patients with ulcerative colitis or Crohn's disease, as their condition may by exacerbated (see section UNDESIRABLE EFFECTS).

Hepatic effects
Close medical surveillance is required when prescribing Voltaren to patients with impaired hepatic function, as their condition may be exacerbated.

As with other NSAIDs, values of one or more liver enzymes may increase. During prolonged treatment with Voltaren (e.g. in the form of tablets or suppositories), regular monitoring of hepatic function is indicated as a precautionary measure. If abnormal liver function tests persist or worsen, if clinical signs or symptoms consistent with liver disease develop, or if other manifestations occur (e.g. eosinophilia, rash), Voltaren should be discontinued. Hepatitis may occur without prodromal symptoms.

Caution is called for when using Voltaren in patients with hepatic porphyria, since it may trigger an attack.

Renal effects
As fluid retention and oedema have been reported in association with NSAID therapy, particular caution is called for in patients with impaired cardiac or renal function, history of hypertension, the elderly, patients receiving concomitant treatment with diuretics or medicinal products that can significantly impact renal function, and in those patents with substantial extracellular volume depletion of any cause, e.g. before or after major surgery (see section CONTRAINDICATIONS). Monitoring of renal function is recommended as a precautionary measure when using Voltaren in such cases. Discontinuation of therapy is normally followed by recovery to the pre-treatment state.

Haematological effects
During prolonged treatment with Voltaren, as with other NSAIDs, monitoring of the blood count is recommended. Like other NSAIDs, Voltaren may temporarily inhibit platelet aggregation. Patients with defects of haemostasis should be carefully monitored.

1    2    3











Health news
Cardiovascular Guide
Natural Remedies
Treatment of Cancer
Women's Health
Irritable bowel syndrome
Common Childhood Illnesses
Prescribed Drugs